Race Oncology Limited September 2024 Quarterly Activity Report & Appendix 4C

Race Oncology Limited (ASX: RAC) presented its Q1 FY2025 quarterly report for the period ended 30 September 2024. At the end of September 2024, Race had AU$14.62 million in cash and cash equivalents, a robust financial position that provides a solid foundation for future growth. Over 70% of spending in the quarter was dedicated to R&D activities, demonstrating Race's commitment to innovation and progress. The Q1 quarter marked a period of transformation for Race, with significant changes to the board. Ms. Mary Harney, Race Chair, and Mr. Philip Lynch, NED, retired from the Race board. In their place, Dr. Pete Smith was appointed Executive Chair, and Drs. Daniel Tillett and Serge Scrofani joined the board as Managing Director and NED, respectively.

Additionally, Race welcomed the esteemed clinical researcher Professor Daniel Von Hoff to its Clinical Advisory Board. Notably, Race also made substantial progress in advancing its clinical program for RC220 bisantrene as a cardioprotective anticancer treatment, including completing all regulatory paperwork required for human ethics submission in H2 CY2024. Furthermore, Race received an R&D Tax Incentive Advance and Overseas Finding Assessment for up to AU$20 million over three years for eligible R&D activities outside Australia.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com